Pfizer OTCs
This article was originally published in The Tan Sheet
Executive Summary
Pfizer Consumer Healthcare "has eliminated select contract sales forces in North America [and] reduced its advertising-agency expenditures through lowered fee structures and ongoing agency consolidation around the world on certain small and/or low-growth brands," the firm reports during third-quarter earnings announcement Oct. 20. Such efforts will lead to "increased value by better leveraging research across the business," Pfizer adds. Consumer division sales were $921 mil. worldwide, an 8% increase over sales of $851 mil. during the prior-year period. U.S. sales for the division were up 9% to $493 mil., compared to $453 mil. last year. Sales for the entire firm totaled $12.2 bil., a 5% increase over 2004...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.